Background: Biosimilar versions of rituximab have similar safety and efficacy as the reference product across all indications based on the extrapolation principle. Our organization replaced intravenous (IV) rituximab (Mabthera) with IV rituximab (Truxima-Biosimilar) in 2021. Hence, our practice changed to providing first cycles of IV rituximab (Truxima-Biosimilar) instead of rituximab (Mabthera), and if the first cycle was completed without severe infusion-related reactions (IRRs), then subsequent cycles were given with subcutaneous (SC) rituximab as per institutional guidelines. However, the safety of this approach has not been evaluated. Methods: A retrospective study was conducted at the Princess Nourah Oncology Center in Saudi Arabia. The primary objective was to assess IRRs after using IV rituximab (Truxima-Biosimilar) in the first cycle followed by SC rituximab in subsequent cycles. Results: Of the 71 patients reviewed, 35 patients met the eligibility criteria. Only one (3%) patient developed an IRR. However, it was a Grade 1 IRR, as per CTCAE.V5, and the patient was able to complete the remaining IV infusion successfully. Hence, all patients transitioned from IV rituximab biosimilar to SC rituximab Mabthera. Conclusions: This real-world study demonstrates that transitioning from IV rituximab biosimilar to SC Mabthera is a well-tolerated and safe practice, confirming the extrapolation principle of biosimilars.
Background: Biosimilar versions of Rituximab have the same safety profile and efficacy as the reference prod-uct across all indications for which it is approved based on the extrapolation principle. Our organization had replaced IV Rituximab (Mabthera) with IV Rituximab (Truxima-Biosimilar) in 2021. Hence, practice was changed to give first cycles of IV Rituximab (Truxima-Biosimilar) instead of Rituximab (Mabthera) and if first cycle was completed without severe infusion related reactions (IRRs) then subsequent cycles were given with subcutaneous Rituximab as per institutional guidelines. There is no evidence of the safety of this practice. Therefore, we decided to evaluate the safety of this practice in retrospective fashion. Objective: The primary objective was to assess IRRs after using Rituximab (Truxima-Biosimilar) instead of Rituximab (Mabthera) IV in-jection in the first cycle followed by subcutaneous rituximab in subsequent cycles. While secondary objective was to determine the overall response rate (ORR). Methods: A retrospective observational study was con-ducted at Princess Nourah Oncology Center (PNOC) in Jeddah, Saudi Arabia. Results: Seventy-one patients were reviewed, and 35 patients met the eligibility criteria. Only one (3%) out of 35 patients developed IRR. However, it was only grade 1 IRR as per CTC.AE V5 and this patient was able to complete the rest of Rituxi-mab infusion intravenously (IV) in the first cycle successfully. Hence all patients transitioned from IV Rituxi-mab biosimilar to subcutaneous (SC) Rituximab Mabthera. Conclusions: We conclude from our real-world evidence study that transition from IV Rituximab biosimilar to SC Rituximab Mabthera is well tolerated and safe practice and confirms the extrapolation principle of biosimilars.